TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Selling and Marketing Expense USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Selling and Marketing Expense history and growth rate from 2010 to 2024.
  • Teva Pharmaceutical Industries Ltd Selling and Marketing Expense for the quarter ending March 31, 2024 was $608 M, a 11.4% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Selling and Marketing Expense for the twelve months ending March 31, 2024 was $2.4 B, a 7.68% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Selling and Marketing Expense for 2023 was $2.34 B, a 3.14% increase from 2022.
  • Teva Pharmaceutical Industries Ltd annual Selling and Marketing Expense for 2022 was $2.27 B, a 6.75% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Selling and Marketing Expense for 2021 was $2.43 B, a 2.76% decline from 2020.
Selling and Marketing Expense, Trailing 12 Months (USD)
Selling and Marketing Expense, Quarterly (USD)
Selling and Marketing Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $2.4 B $608 M +$62 M +11.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $2.34 B $611 M +$63 M +11.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 $2.27 B $576 M +$37 M +6.87% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $2.24 B $603 M +$9 M +1.52% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $2.23 B $546 M -$38 M -6.51% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $2.27 B $548 M -$84 M -13.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 $2.35 B $539 M -$58 M -9.72% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $2.41 B $594 M -$21 M -3.42% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $2.43 B $584 M -$1 M -0.17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.43 B $632 M -$51 M -7.47% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $2.48 B $597 M -$8 M -1.32% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $2.49 B $615 M +$18 M +3.02% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 $2.47 B $585 M -$28 M -4.57% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $2.5 B $683 M -$22 M -3.12% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 $2.52 B $605 M +$10 M +1.68% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $2.51 B $597 M -$69 M -10.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 $2.58 B $613 M -$35 M -5.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 $2.61 B $705 M -$92 M -11.5% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 $2.71 B $595 M -$104 M -14.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $2.81 B $666 M -$16 M -2.35% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $2.83 B $648 M -$90 M -12.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $2.92 B $797 M +$147 M +22.6% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 $2.77 B $699 M -$144 M -17.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $2.91 B $682 M -$262 M -27.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $3.18 B $738 M -$220 M -23% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $3.4 B $650 M -$479 M -42.4% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 $3.87 B $843 M -$97 M -10.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $3.97 B $944 M -$8 M -0.84% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $3.98 B $958 M +$119 M +14.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $3.86 B $1.13 B +$213 M +23.3% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $3.65 B $940 M +$160 M +20.5% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $3.49 B $952 M +$92 M +10.7% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $3.4 B $839 M -$83 M -9% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $3.48 B $916 M -$90 M -8.95% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $3.57 B $780 M -$170 M -17.9% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $3.74 B $860 M -$61 M -6.62% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $3.8 B $922 M -$62 M -6.3% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $3.86 B $1.01 B -$126 M -11.1% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $3.99 B $950 M -$21 M -2.16% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $4.01 B $921 M -$61 M -6.21% Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $4.07 B $984 M -$11 M -1.11% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 $4.08 B $1.13 B +$76 M +7.2% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 $4 B $971 M +$57 M +6.24% Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 $3.95 B $982 M +$1 M +0.1% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 $3.95 B $995 M +$67 M +7.22% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 $3.88 B $1.06 B +$20 M +1.93% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 $3.86 B $914 M +$108 M +13.4% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $3.75 B $981 M +$177 M +22% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $3.57 B $928 M +$96 M +11.5% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $3.48 B $1.04 B +$215 M +26.2% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $3.26 B $806 M +$55 M +7.32% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $3.21 B $804 M +$160 M +24.8% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $3.05 B $832 M +$80 M +10.6% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $2.97 B $821 M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $751 M Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $644 M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $752 M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.